Indeed, co-occurrence of NPM1 and FLT3, either when the latter harbors the more common ITD or the less frequent D835 point mutations, significantly improves the response and the survival outcomes over that of an isolated FLT3 mutation, thus defining a highly favorable prognostic AML group [113]. This evidence concerns the gene NPM1 and acute myeloid leukemia.